Corticotropin-releasing hormone (CRH) is expressed in the human cervical carcinoma cells (HeLa) and upregulates the expression of Fas ligand

Tumor Biology

Volumn 34, Issue 1, 2013, Pages 125-130

  Taliouri, Eirini ^a   Vrekoussis, Thomas ^a   Vergetaki, Aikaterini ^a   Agorastos, Theodore ^b   Makrigiannakis, Antonis ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

Cervical cancer cell line; Expresses CRH; HeLa

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; FAS LIGAND;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA TRANSLATION; UTERINE CERVIX CARCINOMA;

EID: 84872817757     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0519-8     Document Type: Article

References (34)

1. Kalantaridou SN, Zoumakis E, Makrigiannakis A, et al. Corticotropin-releasing hormone, stress and human reproduction: an update. J Reprod Immunol. 2010;85:33-9.
2. Bonfiglio JJ, Inda C, Refojo D, et al. The corticotropin-releasing hormone network and the hypothalamic-pituitary-adrenal axis: molecular and cellular mechanisms involved. Neuroendocrinology. 2011;94:12-20.
3. Kalantaridou SN, Makrigiannakis A, Zoumakis E, Chrousos GP. Stress and the female reproductive system. J Reprod Immunol. 2004;62(1-2):61-8.
4. Kalantaridou SN, Makrigiannakis A, Mastorakos G, Chrousos GP. Roles of reproductive corticotropin-releasing hormone. Ann N Y Acad Sci. 2003;997:129-35.
5. Bartek J, Mistrik M, Bartkova J. Thresholds of replication stress signaling in cancer development and treatment. Nat Struct Mol Biol. 2012;19(1):5-7.
6. Walker PR, Saas P, Dietrich PY, et al. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol. 1997;158:4521-4.
7. Ciocca DR, Puy LA, Fasoli LC, et al. Corticotropin-releasing hormone, luteinizing hormone releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients. Breast Cancer Res Treat. 1990;15:175-84.
8. Miceli F, Ranelletti FO, Martinelli E, et al. Expression and subcellular localization of CRH and its receptors in human endometrial cancer. Mol Cell Endocrinol. 2009;305:6-11.
9. Minas V, Rolaki A, Kalantaridou SN, et al. Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. Br J Cancer. 2007;97:637-45.
10. Makrigiannakis A, Zoumakis E, Kalantaridou S, et al. Corticotropin- releasing hormone promotes blastocyst implantation and early maternal tolerance. Nat Immunol. 2001;2:1018-24.
11. Ehrenschwender M, Wajant H. The role of FasL and Fas in health and disease. Adv Exp Med Biol. 2009;647:64-93.
12. Mountz JD, Zhou T, Bluethmann H, et al. Apoptosis defects analyzed in TcR transgenic and fas transgenic lpr mice. Int Rev Immunol. 1994;11:321-42.
13. Lettau M, Paulsen M, Schmidt H, et al. Insights into the molecular regulation of FasL (CD178) biology. Eur J Cell Biol. 2010;90:456-66.
14. Grino M, Chrousos GP, Margioris AN. The corticotropin releasing hormone gene is expressed in human placenta. Biochem Biophys Res Commun. 1987;148(3):1208-14.
15. Kalantaridou S, Makrigiannakis A, Zoumakis E, et al. Peripheral corticotropin-releasing hormone is produced in the immune and reproductive systems: actions, potential roles and clinical implications. Front Biosci. 2007;12:572-80.
16. Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol. 2009;5:374-81.
17. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540-50.
18. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002;71(6):907-20.
19. Kim R, Emi M, Tanabe K, et al. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer. 2004;100(11):2281-91.
20. Okada K, Komuta K, Hashimoto S, et al. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res. 2000;6:3560-4.
21. Mottolese M, Buglioni S, Bracalenti C, et al. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer. 2000;89:127-32.
22. Ito Y, Monden M, Takeda T, et al. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer. 2000;82:1211-7.
23. Niehans GA, Brunner T, Frizelle SP, et al. Human lung carcinomas express Fas ligand. Cancer Res. 1997;57:1007-12.
24. Saas P, Walker PR, Hahne M, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest. 1997;99:1173-8.
25. Shibakita M, Tachibana M, Dhar DK, et al. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin Cancer Res. 1999;5:2464-9.
26. Kim YS, Kim KH, Choi JA, et al. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors. Arch Pathol Lab Med. 2000;124:687-93.
27. Munakata S, Enomoto T, Tsujimoto M, et al. Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer. 2000;82:1446-52.
28. Ibrahim R, Frederickson H, Parr A, et al. Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism. Cancer. 2006;106:1065-77.
29. Reesink-Peters N, Hougardy BM, van den Heuvel FA, et al. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol. 2005;96:705-13.
30. Zhou JH, Chen HZ, Ye F, et al. Fas-mediated pathway and apoptosis in normal cervix, cervical intraepithelial neoplasia and cervical squamous cancer. Oncol Rep. 2006;16:307-11.
31. Münger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004;78(21):11451-60.
32. Stanley MA. Immune responses to human papilloma viruses. Indian J Med Res. 2009;130(3):266-76.
33. Cohen S, Janicki-Deverts D, Doyle WJ, et al. Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc Natl Acad Sci U S A. 2012;109(16):5995-9.
34. Tay SK. Cervical cancer in the human papillomavirus vaccination era. Curr Opin Obstet Gynecol. 2012;24:3-7.